Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9180184-B2
Publication Date
2015-11-10
Expiration Date
Abstract
This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions.
Core Innovation
The invention relates to immune-modulating adjuvant compositions that enhance antigen immunogenicity. The compositions include free mustard seed oil combined with a catechin or a derivative or salt thereof, and a vitamin selected from Vitamin A, Vitamin E, Vitamin D, and Vitamin C or a derivative or salt thereof. In a specific embodiment, the catechin is epigallocatechin gallate (EGCG).
The disclosed adjuvant compositions are described in formulations where an antigen may be included. Immune response modulation is described by administering the adjuvant-containing compositions to a subject, with effects on immune response elements including antibody responses and TH1/TH2/Treg responses.
The document further describes administration and formulation use across mucosal and systemic routes, including intranasal, sublingual, and intramuscular, with mucosal outcomes including vaginal lavage responses. Experimental examples are described showing enhanced IgG and IgA titers and modulation signals associated with IFN-gamma, IL-5, and IL-10 in mouse vaccination models using antigens including influenza HA and HIV gp120.
Claims Coverage
The partial claims set includes two independent composition claims and associated inventive features focused on free mustard seed oil, a catechin or EGCG, and a vitamin selection; additional inventive features include optional allyl isothiocyanate and immune-response modulation by administering the adjuvant via selected routes.
Mustard oil–catechin–vitamin adjuvant triad
An adjuvant comprising free mustard seed oil, a catechin or a derivative or salt thereof, and a vitamin selected from Vitamin A, Vitamin E, Vitamin D, Vitamin C, and a derivative or salt thereof.
Mustard oil–EGCG–vitamin adjuvant triad
An adjuvant comprising free mustard seed oil, epigallocatechin gallate (EGCG), and a vitamin selected from Vitamin A, Vitamin E, Vitamin D, Vitamin C, and a derivative or salt thereof.
Optional allyl isothiocyanate addition
The adjuvant further comprises allyl isothiocyanate.
Immune response modulation by administering the adjuvant
A method for modulating an immune response in a subject by administering the adjuvant described in the relevant adjuvant claim.
Administration route selection for immune modulation
The method is administered via one selected route from intranasal, pulmonary, sublingual, oral, buccal, ocular, intra-vaginal, intra-rectal, intradermal, and intramuscular.
Adjuvant making by admixing components
A method for making the adjuvant by admixing free mustard seed oil, epigallocatechin gallate (EGCG) or a catechin as applicable, and a vitamin.
Across the independent claims, the core claim coverage is directed to immune-modulating adjuvant compositions built from free mustard seed oil plus either a catechin or specifically EGCG, together with a vitamin selected from Vitamin A, Vitamin E, Vitamin D, and Vitamin C or their derivatives/salts. Dependent coverage adds optional allyl isothiocyanate and extends to immune response modulation via administration of the adjuvant, optionally with an antigen, using defined administration routes.
Stated Advantages
Enhanced antigen immunogenicity.
Enhanced IgG and IgA titers.
Modulation of TH1/TH2/Treg responses, including modulation signals associated with IFN-gamma, IL-5, and IL-10.
Mucosal antibody responses including vaginal lavage antibody responses.
Documented Applications
Mouse vaccination models using influenza HA antigen to demonstrate immune response modulation and enhanced IgG/IgA responses.
Mouse vaccination models using HIV gp120 (cn54) antigen to demonstrate immune response modulation and enhanced IgG/IgA responses.
Mucosal administration with described outcomes including vaginal lavage antibody responses.
Use of intranasal and intramuscular administration routes within the described immune modulation and vaccination models.
Interested in licensing this patent?